Consumer group calls on AstraZeneca to pull Crestor ads

Share this article:
Consumer advocacy group, Public Citizen, is calling on AstraZeneca to pull its latest newspaper ads for Crestor, charging that the ads make false claims about FDA's  concerns over the drug's safety.
"I urge that the FDA immediately stop AstraZeneca from running this or any other misleading advertising about Crestor," wrote Public Citizen's health research group director, Sidney Wolfe, in a letter sent to the FDA's acting commissioner, Lester Crawford, last week.
"The FDA has confidence in the safety and efficacy of Crestor," states  the full-page, color ads that began appearing in The New York Times, USA Today and The Wall Street Journal earlier this month, soon after a veteran FDA scientist named the drug as one of five currently marketed drugs that need more scrutiny.
However, the ad claims that the "concerns that have been raised have no medical or scientific basis."
Calling Public Citizen's concerns "absurd," an AstraZeneca spokesman told Reuters, "We've been assured at the highest level of the FDA that there are no new concerns with Crestor."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...